# Rivastigmine

## Exelon Patch 5

| TAH Drug Code      | [EEXEP](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=EEXEP)                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Mild to moderate Alzheimer's disease dementia.                                                                                                                                                                                                                                                                                                                                                                               |
| Dosing             | Mild-to-moderate Alzheimer’s dementia: Initial, 4.6 mg/24 hours patch (Exelon patch 5) topically once daily; after a minimum of 4 weeks and good tolerability, may titrate dose to 9.5 mg/24 hours patch (Exelon patch 10) topically once daily. Conversion from oral therapy: If oral daily dose <6 mg, switch to 4.6 mg/24 hours patch. Apply patch on the next day following last oral dose.                              |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                |
| Contraindications  | Hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the product. History of application site reactions with prior use of the transdermal patch that indicate allergic contact dermatitis.                                                                                                                                                                                                  |
| Adverse Effects    | More frequent: diarrhea; weight loss; Iindigestion; loss of strength ; nausea; vomiting; loss of appetite; abdominal pain; confusion; constipation; depression; dizziness; fatigue ; headache; insomnia Less frequent: high blood pressure; fainting; general feeling of discomfort or illness; increased sweating; runny nose. Rare: aggression; seizures; trembling and shaking of hands and fingers; trouble in urinating |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                 |
| More Info          | [UpToDate](https://www.uptodate.com/contents/rivastigmine-drug-information)                                                                                                                                                                                                                                                                                                                                                  |

## Rivast 2mg/mL, 120mL solution

##### 臨採

| TAH Drug Code      | [LRIV](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=LRIV)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Mild to moderate dementia associated with Alzheimer's disease. Mild to moderate dementia associated with Parkinson's disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Dosing             | Initial, 1.5 mg orally twice daily for 2 weeks. Titration, if well tolerated, increase in increments of 1.5 mg orally twice daily at minimum of every 2 weeks; Maximum 12 mg/day.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Hypersensitivity to rivastigmine, carbamate derivatives, or other components of the product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Adverse Effects    | Common Endocrine metabolic: Weight loss (26%, female; 18%, male ) Gastrointestinal: Abdominal pain (13% ), Diarrhea (7% to 19% ), Indigestion (9% ), Loss of appetite (6% to 17% ), Nausea (29% to 47% ), Vomiting (13% to 31% ) Neurologic: Asthenia (4% to 6% ), Dizziness (6% to 21% ), Headache (4% to 17% ), Tremor (4% to 23% ) Serious Cardiovascular: Atrial fibrillation (1% or more ), Atrioventricular block (0.1% to 1% ), Myocardial infarction (1% or more ), Peripheral ischemia (0.1% to 1% ), Sick sinus syndrome (0.1% to 1% ) Endocrine metabolic: Hypokalemia (1% or more ), Hyponatremia (0.1% to 1% ) Gastrointestinal: Gastrointestinal hemorrhage (0.1% to 1% ), Hematemesis (0.1% to 1% ), Melena (0.1% to 1% ), Pancreatitis (0.1% to 1% ), Rectal hemorrhage (0.1% to 1% ), Rupture of esophagus Hepatic: Gamma-glutamyl transferase raised (0.1% to 1% ), Hepatitis, Liver function tests abnormal (0.1% to 1% ) Neurologic: Cerebrovascular accident, Intracranial hemorrhage (0.1% to 1% ), Seizure (1% or more ), Transient ischemic attack (1% or more ) Ophthalmic: Glaucoma (0.1% to 1% ) Psychiatric: Suicidal behavior Renal: Acute renal failure (0.1% to 1% ) Respiratory: Bronchospasm (0.1% to 1% ) |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| More Info          | [UpToDate](https://www.uptodate.com/contents/rivastigmine-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

## Exelon 3mg

| TAH Drug Code      | [OEXE](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OEXE)                                                                                                                  |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Mild to moderate dementia associated with Alzheimer's disease. Mild to moderate dementia associated with Parkinson's disease.                                                         |
| Dosing             | Initially 1.5 mg BID for 2 weeks. If well tolerated, increase in increments of 1.5 mg orally twice daily at minimum of every 2 weeks. Maintenance: 3-12 mg daily. Maximun: 12 mg/day. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                         |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                         |
| Contraindications  | Hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the product.                                                                                    |
| Adverse Effects    | Nausea, vomiting, diarrhea, abdominal pain, loss of appetite, dyspepsia, dizziness, headache. Gastrointestinal: Diarrhea (6% ), Nausea (7% ), Vomiting (6% )                          |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                          |
| More Info          | [UpToDate](https://www.uptodate.com/contents/rivastigmine-drug-information)                                                                                                           |

